Pittsburgh Biotech Startup Files Bankruptcy, Can’t Make Payroll Without Court Approval
What happens to the research now
Lipella Pharmaceuticals CEO Jonathan Kaufman told investors in June his Pittsburgh biotech was “fundamentally strong, both operationally and clinically.” Nine months later, on March 30, he filed for bankruptcy. The company couldn’t pay six employees $56,000 in wages without asking a federal judge for permission.
To understand how Lipella went from “strong” to broke in just nine months, you have to look at the “burn.” In the biotech world, “burn” is the cash a company spends every month just to keep the lights on and the research moving. For Lipella, that was about $465,000 a month.
That money was being invested in development of a specialized mouthwash designed to treat a painful, chronic condition called oral lichen planus.
Last spring, CEO Jonathan Kaufman was optimistic, raising millions from investors. But by November, the company admitted there was “substantial doubt” they could even stay in business, according to SEC filings.
The November 14, 2025 quarterly report included an explicit warning to investors under a section titled “Going Concern.”
“These factors individually and collectively raise substantial doubt about the Company’s ability to continue as a going concern,” the filing stated. “The accompanying unaudited condensed financial statements do not include any adjustments that may result from this uncertainty.”
The report detailed Lipella’s accumulated deficit of $19.2 million since the company’s founding in 2005.
The filing warned that if Lipella couldn’t raise more money, “the Company may be forced to curtail or cease operations or file for bankruptcy protection or pursue a dissolution of and liquidation of all of the Company’s remaining assets.”
Kaufman and CFO Doug Johnston signed the report certifying its accuracy.
By the time they filed for Chapter 11 bankruptcy this Monday, they had to ask a judge’s emergency permission just to pay their six remaining employees about $56,000 in back wages and benefits.
Left at the table is a small team: directors of operations and clinical trials, a controller, and a part-time associate.
CEO Jonathan Kaufman is currently working for no salary, and the CFO has agreed to defer his pay starting April 1. The pair staying on essentially to help sell off the company’s patents and data from their recent clinical trials.
The company’s critical research is now in limbo. Lipella’s drug, LP-310, actually finished a Phase 2a trial last fall. It showed the rinse was safe for patients who suffer from oral lichen planus, which can cause painful burning sensations, bleeding during tooth brushing, and discomfort when speaking, chewing, or swallowing. The condition has no FDA-approved treatment.
Lipella held two issued patents in the United States covering the LP-310 formulation, valid until July 11, 2035. The company also held patents in Australia, Canada, and Europe. The bankruptcy filing states Lipella intends to sell these assets through a Section 363 sale process to “maximize value for creditors.” Whether this treatment ever reaches a pharmacy shelf depends entirely on who buys those assets in the coming months.
For the folks who put their money into a “Made in Pittsburgh” success story, the outlook is grim. In these kinds of bankruptcy cases, investors often see less than ten cents on the dollar.
The company's next major deadline is April 13, when it must file complete financial schedules with the bankruptcy court showing all creditors and debts. A reorganization plan is due by July 28.
For now, research appears to have ceased, and the future of a potential Pittsburgh-born treatment is unknown.
We’ll keep an eye on those court filings as the sale moves forward.
MESSAGE ME — Are you seeing something broken in how platforms operate? Work at a company with misleading practices? Have internal docs that contradict public messaging? I want to hear from you. Email me at cereeseblose@gmail.com or message me on Signal: cereeseblose.57
Cereese Receipts is an independent publication. I believe understanding economy, business and tech should be accessible to everyone.
If you enjoy my writing, you can support it by sharing, commenting, or liking—or by sending a small donation through Buy Me a Coffee. It’s an easy way to say thanks and support independent writing.
Partnered with Capital One Venture
I began using this card well before the partnership. If a travel rewards card is on your list, my referral link gets you a welcome offer when you’re approved. Takes two minutes to apply.